Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNA NASDAQ:CRIS NASDAQ:IDRA NASDAQ:INMB NASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsCRISCuris$1.45-4.9%$1.68$1.02▼$5.51$18.06M3.8696,194 shs64,610 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsINMBINmune Bio$1.84-1.3%$2.16$1.71▼$11.64$48.78M1.041.39 million shs281,707 shsVXRTVaxart$0.37+6.4%$0.37$0.26▼$0.98$84.64M1.392.54 million shs535,459 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRISCuris0.00%-7.88%-16.48%-19.15%-71.32%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INMBINmune Bio0.00%-10.58%-7.46%-12.26%-63.81%VXRTVaxart0.00%-4.14%-10.90%-16.57%-55.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsCRISCuris$1.45-4.9%$1.68$1.02▼$5.51$18.06M3.8696,194 shs64,610 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsINMBINmune Bio$1.84-1.3%$2.16$1.71▼$11.64$48.78M1.041.39 million shs281,707 shsVXRTVaxart$0.37+6.4%$0.37$0.26▼$0.98$84.64M1.392.54 million shs535,459 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRISCuris0.00%-7.88%-16.48%-19.15%-71.32%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INMBINmune Bio0.00%-10.58%-7.46%-12.26%-63.81%VXRTVaxart0.00%-4.14%-10.90%-16.57%-55.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAAllena Pharmaceuticals 0.00N/AN/AN/ACRISCuris 2.00Hold$17.001,076.47% UpsideIDRAIdera Pharmaceuticals 0.00N/AN/AN/AINMBINmune Bio 2.38Hold$18.50908.17% UpsideVXRTVaxart 3.00Buy$2.00440.98% UpsideCurrent Analyst Ratings BreakdownLatest VXRT, IDRA, ALNA, CRIS, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CRISCurisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025INMBINmune BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CRISCurisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025INMBINmune BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/ACRISCuris$10.91M1.66N/AN/A($0.71) per share-2.04IDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AINMBINmune Bio$50K975.67N/AN/A$1.45 per share1.27VXRTVaxart$47.40M1.79N/AN/A$0.26 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/ACRISCuris-$43.39M-$4.88N/AN/AN/A-341.24%N/A-102.22%11/13/2025 (Estimated)IDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/AINMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)VXRTVaxart-$66.95M-$0.25N/AN/AN/A-122.63%-91.89%-38.40%11/12/2025 (Estimated)Latest VXRT, IDRA, ALNA, CRIS, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025INMBINmune Bio-$0.31N/AN/AN/AN/AN/A8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A8/5/2025Q2 2025CRISCuris-$1.99-$0.68+$1.31-$0.68$2.64 million$2.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAAllena PharmaceuticalsN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAAllena PharmaceuticalsN/A1.581.58CRISCurisN/A0.740.74IDRAIdera PharmaceuticalsN/A1.561.56INMBINmune BioN/A4.204.20VXRTVaxartN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAAllena Pharmaceuticals7.33%CRISCuris29.97%IDRAIdera Pharmaceuticals12.18%INMBINmune Bio12.72%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipALNAAllena Pharmaceuticals3.70%CRISCuris5.70%IDRAIdera Pharmaceuticals5.05%INMBINmune Bio35.70%VXRTVaxart2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableCRISCuris6012.50 million11.79 millionNo DataIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableINMBINmune Bio1026.59 million17.09 millionOptionableVXRTVaxart120228.94 million222.37 millionOptionableVXRT, IDRA, ALNA, CRIS, and INMB HeadlinesRecent News About These CompaniesVaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Here's What HappenedOctober 10 at 6:43 AM | marketbeat.comVaxart, Inc. to Present Research on Norovirus and COVID-19 Oral Vaccine Programs at World Vaccine Congress Europe 2025October 8, 2025 | quiverquant.comQVaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025October 8, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - Here's WhySeptember 30, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Share Price Passes Below Two Hundred Day Moving Average - What's Next?September 20, 2025 | marketbeat.comVaxart Announces Withdrawal of Reverse Stock Split ProposalSeptember 19, 2025 | markets.businessinsider.comVaxart, Inc. Withdraws Reverse Stock Split Proposal to Focus on Oral Vaccine DevelopmentSeptember 19, 2025 | quiverquant.comQVaxart Withdraws Proposal, Cancels Stockholder MeetingSeptember 19, 2025 | tipranks.comConcerned Vaxart Stockholders Respond to Inadequate Governance AnnouncementsSeptember 18, 2025 | markets.businessinsider.comVaxart Appoints W. Mark Watson as Lead Independent DirectorSeptember 17, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below 200 Day Moving Average - Should You Sell?September 14, 2025 | marketbeat.comConcerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special MeetingSeptember 10, 2025 | markets.businessinsider.comVaxart Reports Promising Phase 1 Results for Second-Generation Norovirus Vaccine Inducing Increased Fecal IgA ResponseSeptember 10, 2025 | quiverquant.comQVaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine CandidateSeptember 10, 2025 | globenewswire.comConcerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special MeetingSeptember 10, 2025 | globenewswire.comVaxart Announces Adjournment of Special Meeting of StockholdersSeptember 8, 2025 | globenewswire.comVaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025September 3, 2025 | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of DirectorsSeptember 3, 2025 | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.September 2, 2025 | globenewswire.comConcerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board AccountabilitySeptember 2, 2025 | globenewswire.comVaxart Granted Extension by Nasdaq to Regain ComplianceAugust 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVXRT, IDRA, ALNA, CRIS, and INMB Company DescriptionsAllena Pharmaceuticals NASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Curis NASDAQ:CRIS$1.44 -0.08 (-4.93%) As of 01:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Idera Pharmaceuticals NASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.INmune Bio NASDAQ:INMB$1.84 -0.03 (-1.34%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Vaxart NASDAQ:VXRT$0.37 +0.02 (+6.39%) As of 01:14 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
